<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND OBJECTIVES: Since the introduction of highly active antiretroviral therapy (HAART), non-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> defining <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> including <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) have emerged as major health concerns for people living with HIV </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: From a prospective database of 11,112 HIV seropositive individuals, we identified 11 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Clinicopathological details on the presentation, treatment and outcomes were collected </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: <z:hpo ids='HP_0000001'>All</z:hpo> were male with a median age of 50 years (range 36-67) and median duration of <z:e sem="disease" ids="C0019693" disease_type="Disease or Syndrome" abbrv="">HIV infection</z:e> of 7.2 years (range 0-21) </plain></SENT>
<SENT sid="4" pm="."><plain>Five had <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> at presentation, including 1 patient with a <z:e sem="disease" ids="C0262584" disease_type="Neoplastic Process" abbrv="">small cell cancer</z:e> of the rectum </plain></SENT>
<SENT sid="5" pm="."><plain>Patients were treated along conventional lines for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> with concomitant HAART and <z:e sem="disease" ids="C0029118" disease_type="Disease or Syndrome" abbrv="">opportunistic infection</z:e> prophylaxis </plain></SENT>
<SENT sid="6" pm="."><plain>During treatment, median CD4 cell counts fell from 357/mm(3) at <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> diagnosis to 199/mm(3), although no <z:e sem="disease" ids="C0029118" disease_type="Disease or Syndrome" abbrv="">opportunistic infections</z:e> were recorded </plain></SENT>
<SENT sid="7" pm="."><plain>Three patients have died and the 5-year overall survival measured 65% (95% confidence interval 32-98%) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Treatment for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> reduces cellular immunity and potentially puts HIV patients at risk of <z:e sem="disease" ids="C0029118" disease_type="Disease or Syndrome" abbrv="">opportunistic infections</z:e>; knowledge of HIV status prior to starting treatment is essential </plain></SENT>
<SENT sid="9" pm="."><plain>This risk may be reduced by concomitant HAART and prophylaxis </plain></SENT>
<SENT sid="10" pm="."><plain>Clinicians managing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> should consider screening patients for HIV before starting chemotherapy or radiotherapy </plain></SENT>
</text></document>